Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia

Inclusion Criteria: 1. Age ≥ 18 years old, both male and female; 2. New Diagnosed Chronic Phase Chronic Myeloid Leukemia. 3. Within half a year after diagnosis of CML; 4. Previous TKIs treatment was less than 2 weeks; 5. The pregnant test of female patients was negative (within 7 days before medication before enrollment); 6. Informed consent of the patient or his legal representative Exclusion Criteria: 1. T315I mutation is known to exist; 2. Rare atypical transcript types that cannot be standardized internationally; 3. Received TKI drugs for more than 2 weeks before enrollment; 4. Received interferon therapy for more than 3 months before enrollment; 5. Received other anti-CML drugs (except hydroxyurea) for more than 2 weeks or surgical treatment (including hematopoietic stem cell transplantation) 6. patients who participate in other clinical studies at the same time; 7. patients who having had major surgery or not recovered from surgery within 4 weeks; 8. patients who having history of malignant tumor 9. Woman who is pregnant or nursing 10. Eastern Cooperative Oncology Group Physical Performance Status Score (ECOG PS) \> 3; 11. Patients known to be allergic or contraindicated to the study drug (APIs and/or excipients). 12. A clear history of neurological or psychiatric disorders, including epilepsy or dementia